124 related articles for article (PubMed ID: 14606135)
1. Factor V Leiden and venous thromboembolism: risk associated with hormone replacement therapy.
Park BD; Lookinland S; Beckstrand RL; Chasson S
J Am Acad Nurse Pract; 2003 Oct; 15(10):458-66. PubMed ID: 14606135
[TBL] [Abstract][Full Text] [Related]
2. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.
Herrington DM; Vittinghoff E; Howard TD; Major DA; Owen J; Reboussin DM; Bowden D; Bittner V; Simon JA; Grady D; Hulley SB
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):1012-7. PubMed ID: 12067913
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Rodeghiero F; Tosetto A
Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
[TBL] [Abstract][Full Text] [Related]
4. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
5. The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study.
Douketis JD; Julian JA; Crowther MA; Kearon C; Bates SM; Barone M; Piovella F; Middeldorp S; Prandoni P; Johnston M; Costantini L; Ginsberg JS
Clin Appl Thromb Hemost; 2011; 17(6):E106-13. PubMed ID: 21159708
[TBL] [Abstract][Full Text] [Related]
6. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism in asymptomatic carriers of factor V Leiden mutation from symptomatic families: any role for hormonal replacement treatment?
Procare Group
J Thromb Haemost; 2003 Jun; 1(6):1325-6. PubMed ID: 12871343
[No Abstract] [Full Text] [Related]
9. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Simkova M; Simko F; Kovacs L
Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.
Wu O; Robertson L; Langhorne P; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Brenkel I; Regan L; Greer IA
Thromb Haemost; 2005 Jul; 94(1):17-25. PubMed ID: 16113779
[TBL] [Abstract][Full Text] [Related]
11. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
[TBL] [Abstract][Full Text] [Related]
12. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
Straczek C; Oger E; Yon de Jonage-Canonico MB; Plu-Bureau G; Conard J; Meyer G; Alhenc-Gelas M; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
Circulation; 2005 Nov; 112(22):3495-500. PubMed ID: 16301339
[TBL] [Abstract][Full Text] [Related]
13. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM
Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310
[TBL] [Abstract][Full Text] [Related]
14. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism.
Margaglione M; Brancaccio V; De Lucia D; Martinelli I; Ciampa A; Grandone E; Di Minno G
Chest; 2000 Nov; 118(5):1405-11. PubMed ID: 11083693
[TBL] [Abstract][Full Text] [Related]
15. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
[TBL] [Abstract][Full Text] [Related]
16. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.
Marchiori A; Mosena L; Prins MH; Prandoni P
Haematologica; 2007 Aug; 92(8):1107-14. PubMed ID: 17650440
[TBL] [Abstract][Full Text] [Related]
17. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
Bergrem A; Dahm AE; Jacobsen AF; Mowinckel MC; Sandvik L; Sandset PM
Br J Haematol; 2011 Jul; 154(2):241-7. PubMed ID: 21564075
[TBL] [Abstract][Full Text] [Related]
18. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations.
DeSancho MT; Berlus N; Christos PJ; Rand J
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):11-5. PubMed ID: 19474699
[TBL] [Abstract][Full Text] [Related]
20. A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms.
Bouaziz-Borgi L; Nguyen P; Hezard N; Musharrafieh U; Almawi WY; Mahjoub T
Exp Mol Pathol; 2007 Dec; 83(3):480-3. PubMed ID: 17555744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
